Combination treatment before surgery for HER2-positive rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of treatments given before surgery to shrink locally advanced HER2-positive rectal cancer. If you have this type of cancer, this approach might make surgery more successful and possibly allow you to keep your anus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have locally advanced rectal cancer that has not spread to distant parts of the body.
- The tumor should be within about 2 inches (5 cm) from the anal opening, or show high-risk features on MRI.
- Your tumor must test positive for HER2 (a protein that helps cancer grow) by biopsy.
- You must not have had prior treatment for this cancer, like radiation, chemotherapy, or immunotherapy.
- You should be generally healthy (able to do most daily activities) and between 18 and 75 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs (sintilimab and suvemcitug) to see if it can improve outcomes for patients with locally advanced rectal cancer that has not spread. The goal is to shrink the tumor before surgery, potentially making it easier to remove and reducing the risk of recurrence.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial is testing a new drug combined with radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve the chances of successful surgery.
This trial tests a combination of two immunotherapy drugs and chemotherapy given before surgery for a type of rectal cancer that has a specific genetic marker (MSI-H/dMMR). The goal is to shrink the tumor and improve the chances of successful surgery.
This study tests a combination of chemotherapy, radiation, and an immunotherapy drug (called anti-PD-1) before surgery for rectal cancer that has not spread. The goal is to see if this approach can shrink or eliminate the tumor, potentially improving outcomes.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.